Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demon...

Full description

Saved in:
Bibliographic Details
Main Authors: Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison
Format: article
Language:EN
Published: Nature Portfolio 2018
Subjects:
Mavoglurant
Core Studies
Fragile X Mental Retardation Protein (FMRP)
Repetitive Behavior Scale-Revised (RBS-R)
Extension Study Baseline
Medicine
R
Science
Q
Online Access:https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/b0c86247e00a4aa7a01f18f018f9be46

Similar Items